| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d659932c925df41c36b3f36585fee851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73174563f14b4b55759ee1a2084075d7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f98581508c22d348e456eb726924719f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9deb6bdbb73f86dd8bc84f2196b0bba3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54f128aa748a1304771df3718fb1f800
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d2b3d32ae441f67b653a2da1afa503e |
| publicationDate |
2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11175282-B2 |
| titleOfInvention |
Method for predicting and monitoring clinical response to immunomodulatory therapy |
| abstract |
The present invention provides a method to quantitatively measure the response of a patient to an immune-modulator drug that will aid clinicians in the determination of the optimal combination/posology of immunosuppressant/immune-modulator drugs. In addition, this method will open the possibility for clinicians to make the necessary adjustments in immunosuppressive therapy, as a way to avoid organ rejection to actually take place. Furthermore, this method will significantly reduce side effects of immunosuppressant drugs, optimizing therapeutic scheme and dosages, enabling the determination of the most effective immunosuppression regimen at the lower dosages for each patient individually and monitoring of treatment efficiency along time, thus opening the door to treatment personalization. |
| priorityDate |
2017-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |